Zocovic Dry Syrup is a combination antibiotic formulation containing Amoxycillin 200 mg and Clavulanic Acid 28.5 mg per dose, designed for oral administration. Amoxycillin, a broad-spectrum penicillin antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death, while Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by beta-lactamase-producing resistant bacteria. This synergistic action extends the antibacterial spectrum of Amoxycillin, making Zocovic Dry Syrup effective against a wide range of Gram-positive and Gram-negative pathogens. It is commonly indicated for the treatment of respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, and other bacterial infections susceptible to this combination. The dry syrup formulation is particularly suitable for pediatric patients who have difficulty swallowing tablets. Dosage and duration should be determined by a healthcare professional based on the severity of infection and patient-specific factors. Common side effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. Hypersensitivity reactions, although rare, require immediate medical attention. Zocovic Dry Syrup should be used with caution in patients with a history of penicillin allergy or hepatic impairment. Proper adherence to prescribed dosage is essential to prevent antibiotic resistance.